Market insights predict the global cell therapy manufacturing industry will increase from USD 7.10 billion in 2026 to USD 27 billion by 2035, achieving a CAGR of 16%. The increasing incidences of chronic disorders, growing demand for regenerative medicine, and technological advancements drive the market.
Last Updated : 31 July 2026Category: BiotechnologyInsight Code: 5050Format: PDF / PPT / Excel
Asia-Pacific Cell Therapy Manufacturing Market Size Value (US$) and Volume (Billion Tons), by Indication (2021 – 2033)
HIV
Autoimmune Disorders
Immune Deficiencies
Cancer
Neurological Disorders
Asia-Pacific Cell Therapy Manufacturing Market Size Value (US$) and Volume (Billion Tons), by Route of Administration (2021 – 2033)
Topical
Injectable
Infusion
Implantable Bio-Scaffold
Asia-Pacific Cell Therapy Manufacturing Market Size Value (US$) and Volume (Billion Tons), by Cell Type (2021 – 2033)
Hematopoietic (Blood-Forming) Stem Cells (HSC)
Skeletal Muscle Stem Cells
Mesenchymal Stem Cells
Lymphocytes
Dendritic Cells
Pancreatic Islet Cells
CAR-T Cells
Asia-Pacific Cell Therapy Manufacturing Market Size Value (US$) and Volume (Billion Tons), by End User (2021 – 2033)
Hospital Settings
Intensive Outpatient Treatment Centers
Academic and Research Institutes
Specialty Clinics
Asia-Pacific Cell Therapy Manufacturing Market Size Value (US$) and Volume (Billion Tons), by Country (2021 – 2033)
China
India
Japan
South Korea
Malaysia
Philippines
Latin America Cell Therapy Manufacturing Market Assessment
Overview
Latin America Cell Therapy Manufacturing Market Size Value (US$) and Volume (Billion Tons), by Indication (2021 – 2033)
HIV
Autoimmune Disorders
Immune Deficiencies
Cancer
Neurological Disorders
Latin America Cell Therapy Manufacturing Market Size Value (US$) and Volume (Billion Tons), by Route of Administration (2021 – 2033)
Topical
Injectable
Infusion
Implantable Bio-Scaffold
Latin America Cell Therapy Manufacturing Market Size Value (US$) and Volume (Billion Tons), by Cell Type (2021 – 2033)
Hematopoietic (Blood-Forming) Stem Cells (HSC)
Skeletal Muscle Stem Cells
Mesenchymal Stem Cells
Lymphocytes
Dendritic Cells
Pancreatic Islet Cells
CAR-T Cells
Latin America Cell Therapy Manufacturing Market Size Value (US$) and Volume (Billion Tons), by End User (2021 – 2033)
Hospital Settings
Intensive Outpatient Treatment Centers
Academic and Research Institutes
Specialty Clinics
Latin America Cell Therapy Manufacturing Market Size Value (US$) and Volume (Billion Tons), by Country (2021 – 2033)
Brazil
Rest of Latin America
Middle East & Africa (MEA) Cell Therapy Manufacturing Market Assessment
Overview
Middle East & Africa (MEA) Cell Therapy Manufacturing Market Size Value (US$) and Volume (Billion Tons), by Indication (2021 – 2033)
HIV
Autoimmune Disorders
Immune Deficiencies
Cancer
Neurological Disorders
Middle East & Africa (MEA) Cell Therapy Manufacturing Market Size Value (US$) and Volume (Billion Tons), by Route of Administration (2021 – 2033)
Topical
Injectable
Infusion
Implantable Bio-Scaffold
Middle East & Africa (MEA) Cell Therapy Manufacturing Market Size Value (US$) and Volume (Billion Tons), by Cell Type (2021 – 2033)
Hematopoietic (Blood-Forming) Stem Cells (HSC)
Skeletal Muscle Stem Cells
Mesenchymal Stem Cells
Lymphocytes
Dendritic Cells
Pancreatic Islet Cells
CAR-T Cells
Middle East & Africa (MEA) Cell Therapy Manufacturing Market Size Value (US$) and Volume (Billion Tons), by End User (2021 – 2033)
Hospital Settings
Intensive Outpatient Treatment Centers
Academic and Research Institutes
Specialty Clinics
Middle East & Africa (MEA) Cell Therapy Manufacturing Market Size Value (US$) and Volume (Billion Tons), by Country (2021 – 2033)
GCC
North Africa
South Africa
Rest of the Middle East & Africa
Company Profiles
Merck KGaA
Company Overview
Geographic Footprints
Financial Performance
Product Portfolio
SWOT Analysis
R&D Efforts
Recent Developments & Strategic Collaborations
Product Launch/M&A/Technical Collaboration
Thermo Fisher Scientific
Catalent, Inc
Bio-Techne
Cytiva
Lonza
The Discovery Labs
Novartis AG
Bristol-Myers Squibb Company
Gilead Sciences, Inc.
Conclusion & Recommendations
FAQ's
Answer : Cell therapies are subject to rigorous regulatory scrutiny to ensure safety, efficacy, and quality. Regulatory considerations include compliance with good manufacturing practices, demonstration of product consistency and reproducibility, evaluation of long-term safety and efficacy data, and adherence to regulatory guidelines specific to cell therapies.
Answer : U.S. National Library of Medicine, National Cancer Institute; and International Society for Cell and Gene Therapy
Answer : Cell therapy manufacturing market stands at USD 7.10 billion in 2026 and is expected to reach USD 27 billion by 2035, growing at a CAGR of 16% from 2026 to 2035.
Payal Rabde is a Healthcare Market Research Analyst at Towards Healthcare Research & Consulting with 4+ years of experience in pharmaceuticals, biotechnology, medical devices, and life sciences.
Aditi Shivarkar is a seasoned professional with over 14 years of experience in healthcare
market research. As a content reviewer, Aditi ensures the quality and accuracy of all market
insights and data presented by the research team.
We use cookies that are necessary to make our site work. We may also use additional cookies to analyze,
improve, and personalize our content and your digital experience.
You can manage your cookie preferences using the
Privacy Policy
For more information, see our
Terms and Conditions
.
Cookie Preference Center
We use cookies which are necessary to make our site work.
We may also use additional cookies to analyze, improve and personalize
our content and your digital experience.
For more information, please read our
Cookie Policy
.
You may choose not to allow some types of cookies.
Blocking some cookies may impact your experience of the site.
sales@towardshealthcare.com
+1 804-441-9344
Download Sample
USA : +1 8044 419344
sales@towardshealthcare.com